|
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
|
|
|
|
We are pleased to share the following information about FRUZAQLA® (fruquintinib) that may be important to mCRC commercial patients.
|
|
As of 2/1/25, FRUZAQLA is covered on Express Scripts (ESI) National Formularies. These formularies cover about 25 million lives.
|
|
For commercial patients this means that they will have more rapid access to FRUZAQLA and a lower co-pay.
|
|
We hope that this formulary update helps improve patient access and time to treatment start for FRUZAQLA.
|
|
Please note, FRUZAQLA’s limited distribution network remains unchanged and excludes PBM-owned specialty pharmacies.
|
|
|
|
|
|
|
|
This content is sponsored by Takeda, and ION Oncology Practice Network has not independently reviewed or verified the information provided by Takeda. | | |
